tetano
Editor, Senior Moderator
Neurol Sci
. 2021 Sep 22.
doi: 10.1007/s10072-021-05616-1. Online ahead of print.
Alzheimer's disease in elderly COVID-19 patients: potential mechanisms and preventive measures
Haili Wang[SUP] 1 2 [/SUP], Juan Lu[SUP] 3 [/SUP], Xia Zhao[SUP] 4 [/SUP], Rongyin Qin[SUP] 5 [/SUP], Kangping Song[SUP] 6 [/SUP], Yao Xu[SUP] 2 [/SUP], Jun Zhang[SUP] 7 [/SUP], Yingzhu Chen[SUP] 8 [/SUP]
Affiliations
Abstract
Advanced age correlates with higher morbidity and mortality among patients affected with the novel coronavirus disease 2019 (COVID-19). Because systemic inflammation and neurological symptoms are also common in severe COVID-19 cases, there is concern that COVID-19 may lead to neurodegenerative conditions such as Alzheimer's disease (AD). In this review, we summarize possible mechanisms by which infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, may cause AD in elderly COVID-19 patients and describe preventive measures to mitigate risk. Potential mechanisms include NLRP3 inflammasome activation and IL-1β release, renin-angiotensin system hyperactivation, innate immune activation, oxidative stress, direct viral infection, and direct cytolytic β-cell damage. Anti-inflammatory therapies, including TNF-α inhibitors and nonsteroidal anti-inflammatory drugs, antioxidants such as the vitamin E family, nutritional intervention, physical activity, blood glucose control, and vaccination are proposed as preventive measures to minimize AD risk in COVID-19 patients. Since several risk factors for AD may converge during severe SARS-CoV-2 infection, neurologists should be alert for potential symptoms of AD and actively implement preventive measures in patients presenting with neuropsychiatric symptoms and in high-risk patients such as the elderly.
Keywords: Alzheimer’s disease; COVID-19; Prevention; Renin-angiotensin system; Systemic inflammation.
. 2021 Sep 22.
doi: 10.1007/s10072-021-05616-1. Online ahead of print.
Alzheimer's disease in elderly COVID-19 patients: potential mechanisms and preventive measures
Haili Wang[SUP] 1 2 [/SUP], Juan Lu[SUP] 3 [/SUP], Xia Zhao[SUP] 4 [/SUP], Rongyin Qin[SUP] 5 [/SUP], Kangping Song[SUP] 6 [/SUP], Yao Xu[SUP] 2 [/SUP], Jun Zhang[SUP] 7 [/SUP], Yingzhu Chen[SUP] 8 [/SUP]
Affiliations
- PMID: 34550494
- DOI: 10.1007/s10072-021-05616-1
Abstract
Advanced age correlates with higher morbidity and mortality among patients affected with the novel coronavirus disease 2019 (COVID-19). Because systemic inflammation and neurological symptoms are also common in severe COVID-19 cases, there is concern that COVID-19 may lead to neurodegenerative conditions such as Alzheimer's disease (AD). In this review, we summarize possible mechanisms by which infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, may cause AD in elderly COVID-19 patients and describe preventive measures to mitigate risk. Potential mechanisms include NLRP3 inflammasome activation and IL-1β release, renin-angiotensin system hyperactivation, innate immune activation, oxidative stress, direct viral infection, and direct cytolytic β-cell damage. Anti-inflammatory therapies, including TNF-α inhibitors and nonsteroidal anti-inflammatory drugs, antioxidants such as the vitamin E family, nutritional intervention, physical activity, blood glucose control, and vaccination are proposed as preventive measures to minimize AD risk in COVID-19 patients. Since several risk factors for AD may converge during severe SARS-CoV-2 infection, neurologists should be alert for potential symptoms of AD and actively implement preventive measures in patients presenting with neuropsychiatric symptoms and in high-risk patients such as the elderly.
Keywords: Alzheimer’s disease; COVID-19; Prevention; Renin-angiotensin system; Systemic inflammation.